老年患者中的异柠檬酸脱氢酶突变型低级别胶质瘤:分子特征明确当代队列的治疗与结局
该研究回顾性分析2009至2019年在本院治疗的幕上半球低级别胶质瘤老年患者(>60岁),要求具备分子分型数据及术前术后肿瘤体积,并与60岁以下患者比较。共纳入207例,其中老年患者21例(10%)。老年与年轻患者无进展生存期相当(46 vs 54个月;p=0.634)。作者认为,在条件允许时,老年患者应提倡包括最大安全切除在内的强化治疗。
要点
- 老年患者占分子特征明确低级别胶质瘤的10%(21/207)。
- 老年与年轻患者无进展生存期相当(46 vs 54个月;p=0.634)。
- 作者认为,老年患者只要条件允许,应提倡包括最大安全切除在内的强化治疗。
核心结论
- 老年患者仅占分子特征明确低级别胶质瘤的小部分。
- 与既往报道不同,本系列老年患者取得了与年轻患者相当的良好手术和生存结局。
- 作者认为,老年患者只要条件允许,应提倡包括最大安全切除在内的强化治疗。
研究设计与样本
- 回顾性分析2009至2019年在本院治疗的幕上半球低级别胶质瘤老年患者,并与60岁以下患者比较。
- 纳入要求具备亚型定义分子数据及术前和术后肿瘤体积。
- 共纳入207例患者,其中老年患者21例(10%)。
主要发现
- 老年与年轻患者无进展生存期相当(46 vs 54个月;p=0.634)。
- 少突胶质细胞瘤在老年患者中更常见(76% vs 46%;p=0.011)。
- 多数患者接受肿瘤切除(老年:81% vs 年轻:91%;p=0.246),残留肿瘤体积相当(老年:7.8 cm3;年轻:4.1 cm3;p=0.137)。
- 辅助治疗在老年患者中占76%,年轻患者中占61%(p=0.163)。
- 单因素和多因素生存分析确定肿瘤跨越中线、手术策略以及术前和术后肿瘤体积为预后因素。
临床怎么用
- 作者认为,老年患者只要条件允许,应提倡包括最大安全切除在内的强化治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lower-grade glioma (LGG) is rare among patients above the age of 60 ("elderly"). Previous studies reported poor outcome, likely due to the inclusion of isocitrate dehydrogenase (IDH) wildtype astrocytomas and advocated defensive surgical and adjuvant treatment. This study set out to question this paradigm analyzing a contemporary cohort of patients with IDH mutant astrocytoma and oligodendroglioma WHO grade 2 and 3. METHODS: Elderly patients treated in our department for a supratentorial, hemispheric LGG between 2009 and 2019 were retrospectively analyzed for patient-, tumor- and treatment-related factors and progression-free survival (PFS) and compared to patients aged under 60. Inclusion required the availability of subtype-defining molecular data and pre- and post-operative tumor volumes. RESULTS: 207 patients were included, among those 21 elderlies (10%). PFS was comparable between elderly and younger patients (46 vs. 54 months; p = 0.634). Oligodendroglioma was more common in the elderly (76% vs. 46%; p = 0.011). Most patients underwent tumor resection (elderly: 81% vs. younger: 91%; p = 0.246) yielding comparable residual tumor volumes (elderly: 7.8 cm3; younger: 4.1 cm3; p = 0.137). Adjuvant treatment was administered in 76% of elderly and 61% of younger patients (p = 0.163). Uni- and multi-variate survival analyses identified a tumor crossing the midline, surgical strategy, and pre- and post-operative tumor volumes as prognostic factors. CONCLUSION: Elderly patients constitute a small fraction of molecularly characterized LGGs. In contrast to previous reports, favorable surgical and survival outcomes were achieved in our series comparable to those of younger patients. Thus, intensified treatment including maximal safe resection should be advocated in elderly patients whenever feasible.
引用
- Dao Trong P, Gluszak M, Reuss D, et al. Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort. J Neurooncol. 2023. PMID: 36648586. doi:10.1007/s11060-022-04230-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。